IRS Commissioner Nominee Daniel Werfel Testifies Before Senate Finance Committee
Client Alert | 1 min read | 02.24.23
On February 15th, Daniel Werfel, the nominee for IRS Commissioner, testified before the Senate Finance Committee during his nomination hearing. As expected, Werfel faced tough questioning about how he would oversee the use of $80 billion in new funding coming to the IRS over the next decade. The Inflation Reduction Act, which passed late last year, appropriated the additional funding for the IRS to increase compliance and provide better customer service to taxpayers.
Republicans have criticized the additional funding, citing fears that the investment in the IRS will increase audits of individual and small business taxpayers. Treasury Secretary Janet Yellen addressed this concern, stating that the new funding will not be used to increase the audit rate for households making under $400,000 a year. Werfel committed during his nomination hearing to following Secretary Yellen’s directive.
Werfel testified that, if confirmed, “the audit and compliance priorities will be focused on enhancing the IRS’ capabilities to ensure that America’s highest earners comply with applicable tax laws.” As a result, we expect to see more coordinated and potentially more aggressive audits of high-earning individuals and corporations.
Werfel also testified that, if confirmed, he would focus on modernizing the IRS, improving taxpayer service, overhauling the agency’s technology systems, and adding additional IRS employees in customer service roles and with expertise in complex tax matters. The tax community has lamented the IRS’s customer service capabilities and outdated systems for years and these proposed modernization efforts are a welcome, much needed change.
We will continue to follow the IRS’s enforcement efforts as they develop and provide updates.
Contacts
Insights
Client Alert | 7 min read | 06.26.26
Federal Roundup: Updates for PBMs and Medicare Advantage Organizations
In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future.
Client Alert | 6 min read | 06.26.26
Client Alert | 4 min read | 06.25.26
Twin Executive Orders Seek to Spur Quantum Leap in Technology and Cybersecurity
Client Alert | 7 min read | 06.24.26


